Friday, 25 September 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 26, 2026

Ibotta outlines Q1 2026 revenue guidance of $78M-$82M with LiveLift driving transformation

View original at seekingalpha.com
Ibotta outlines Q1 2026 revenue guidance of $78M-$82M with LiveLift driving transformation Earnings Call Insights: Ibotta, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q4 revenue and adjusted EBITDA were 7% and 31% above the midpoint of Q3 guidance respectively

    80% confidence
  • Companies added additional budget to same brands and added additional brands into the program

    80% confidence
  • Low single-digit sequential revenue growth expected in Q2 versus Q1, and slight year-over-year revenue growth expected in Q3

    80% confidence
  • Q1 2026 revenue expected in range of $78 million to $82 million, representing 5% year-over-year decline at midpoint

    80% confidence
  • LiveLift is the most sophisticated capability and represents where the industry is heading

    80% confidence
  • There's real emphasis on value among clients and Ibotta is well positioned in terms of the macro environment

    80% confidence
  • LiveLift is a TAM expander with ability to provide ongoing, actionable metrics

    80% confidence
  • Q4 revenue and adjusted EBITDA are both above the top end of the guidance range, representing an improvement in year-over-year revenue trends compared to Q3

    80% confidence
  • Outperformance attributed to improved execution, core product strengthening, and expansion of LiveLift

    80% confidence
  • LiveLift allows clients to see projected incremental sales and cost per incremental dollar at various intervals during campaigns, enabling better optimization

    80% confidence
  • More offers, better quality offers, and longer duration on network drive more redemptions per redeemer

    80% confidence
  • Third-party redeemers grew by almost 3.5 million in Q4, with about one-third from existing publishers

    80% confidence
  • Third-party redeemer growth attributed to new publisher partnerships and innovations in in-store and online awareness

    80% confidence
  • Clients can purchase sales lift studies just as they would for other forms of digital media through partnerships with Circana and ABCS Insights

    80% confidence
  • Q1 2026 adjusted EBITDA expected in range of $6 million to $8 million, representing about 9% adjusted EBITDA margin at midpoint

    80% confidence
  • Stock-based compensation expense expected to be approximately $10 million higher than 2025

    80% confidence
  • Broad-based sequential progress in year-over-year redemption revenue trends throughout Q4, with LiveLift revenue better than projected and SNAP program contributing incremental revenue

    80% confidence
  • Average campaign size in LiveLift from companies piloting it is substantially larger than average campaign size in core Ibotta offering from same companies

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
Ibotta outlines Q1 2026 revenue guidance of $78M-$82M with LiveLift driving transformation — Source | Via News | ViaNews EU